213
Views
5
CrossRef citations to date
0
Altmetric
Letters to the editor

Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma

&
Pages 1347-1350 | Received 10 Mar 2010, Accepted 13 Apr 2010, Published online: 19 May 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Adrienne A Phillips, Colette Owens, Sangmin Lee & Govind Bhagat. (2011) An update on the management of peripheral T-cell lymphoma and emerging treatment options. Journal of Blood Medicine 2, pages 119-129.
Read now
Fernando Roncolato, Anna Gazzola, Pier Luigi Zinzani, Stefano A Pileri & Pier Paolo Piccaluga. (2011) Targeted molecular therapy in peripheral T-cell lymphomas. Expert Review of Hematology 4:5, pages 551-562.
Read now
Rebecca A Howman & H Miles Prince. (2011) New drug therapies in peripheral T-cell lymphoma. Expert Review of Anticancer Therapy 11:3, pages 457-472.
Read now
Kieron Dunleavy & Wyndham H. Wilson. (2010) Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma. Leukemia & Lymphoma 51:9, pages 1-2.
Read now

Articles from other publishers (1)

Eva Perez-Pampin, Joaquin Campos-Franco, Jorge Blanco & Antonio Mera. (2013) Remission Induction in a Case of Refractory Behçet Disease With Alemtuzumab. Journal of Clinical Rheumatology 19:2, pages 101-103.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.